HIV/AIDS news from FierceBiotech

In another big blow to the AIDS research field, pharma giant Roche is dumping its R&D work in the field. The Financial Times reports that disappointing clinical results had persuaded Roche to Read more...

Once one of the Triangle's most promising drug developers, Trimeris' largest shareholder is demanding that the company drop just about everything and focus on selling itself. "We are not in favor of Read more...

The rapid move toward offshoring drug trials has sparked controversies over the ethics involved in some of these studies, reports the Financial Times. Take for instance California's Viral Genetics, Read more...

> In October, Novartis announced some job cuts and management changes. Now, CEO Daniel Vasella says he's working on a sweeping overhaul of his company's org chart. Read more...

The fallout over Merck's disastrous AIDS vaccine trial continues. There are new Read more...

Over the weekend Merck announced that it was scrapping development of a promising AIDS vaccine after researchers concluded that it had failed a large international study. This was considered a major Read more...

An FDA expert panel has provided an important endorsement for Merck's experimental AIDS drug Isentress. The twice-a-day pill is the first in a new class of AIDS drugs. If fully approved by the Read more...

Up-start biotech Tobira Therapeutics, which is developing HIV/AIDS drugs, has raised $31 million in its first round of venture capital. Domain Associates and Frazier Healthcare Ventures led the round Read more...

> Advanced Magnetics has announced preliminary positive results from its fourth and final planned Phase III clinical trial of ferumoxytol as an intravenous iron replacement therapeutic in chronic Read more...

The FDA on Tuesday yanked Altus Pharmaceuticals' orphan drug designation for its experimental pancreatic insufficiency therapy, saying the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. The drug--ALTU-135--is intended to treat a rare condition in which a person fails to develop the chemicals and enzymes needed to absorb food. Altus officials say they may consult with the agency about refilling an application.

"We believe that only a …

Read more...